Trametinib-话题@MedSci

#Trametinib#

15篇内容 | 644人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2191828, encodeId=4e8321918286e, content=<a href='/topic/show?id=0a08e451815' target=_blank style='color:#2F92EE;'>#神经胶质瘤#</a> <a href='/topic/show?id=2cd11e738fd' target=_blank style='color:#2F92EE;'>#Trametinib#</a> <a href='/topic/show?id=9799565312' target=_blank style='color:#2F92EE;'>#Dabrafenib#</a>, objectTitle=JCO：复发/难治性儿童高级别胶质瘤的联合用药新疗法, objectType=article, longId=813996, objectId=31158139966f, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/medical-conference-P42ZDP5.jpg, objectUrl=/article/show_article.do?id=31158139966f, replyNumber=0, likeNumber=20, createdTime=2024-03-07, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=31158139966f, moduleTitle=JCO：复发/难治性儿童高级别胶质瘤的联合用药新疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=31158139966f)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1752371, encodeId=91f71e5237160, content=<a href='/topic/show?id=2cd11e738fd' target=_blank style='color:#2F92EE;'>#Trametinib#</a>, objectTitle=J Clin Oncol：III期临床研究评估PD-1抑制剂Spartalizumab 联合Dabrafenib（达拉非尼）+ Trametinib（曲美替尼）治疗BRAF V600突变不可切除或转移性黑色素瘤的疗效, objectType=article, longId=294057, objectId=20b829405e40, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=20b829405e40, replyNumber=0, likeNumber=31, createdTime=2022-05-06, rootId=0, userName=pandamao2022, userId=0da336510503, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=20b829405e40, moduleTitle=J Clin Oncol：III期临床研究评估PD-1抑制剂Spartalizumab 联合Dabrafenib（达拉非尼）+ Trametinib（曲美替尼）治疗BRAF V600突变不可切除或转移性黑色素瘤的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=20b829405e40)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752372, encodeId=89fe1e523727c, content=<a href='/topic/show?id=2cd11e738fd' target=_blank style='color:#2F92EE;'>#Trametinib#</a>, objectTitle=Ann Oncol：II期临床研究ROAR更新：Dabrafenib(达拉菲尼)联合trametinib(曲美替尼)治疗BRAF V600E突变间变性甲状腺癌的疗效, objectType=article, longId=295362, objectId=66af295362ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=66af295362ac, replyNumber=0, likeNumber=31, createdTime=2022-08-23, rootId=0, userName=pandamao2022, userId=0da336510503, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=66af295362ac, moduleTitle=Ann Oncol：II期临床研究ROAR更新：Dabrafenib(达拉菲尼)联合trametinib(曲美替尼)治疗BRAF V600E突变间变性甲状腺癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=66af295362ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752370, encodeId=e30c1e5237011, content=<a href='/topic/show?id=2cd11e738fd' target=_blank style='color:#2F92EE;'>#Trametinib#</a>, objectTitle=NEJM：Dabrafenib联合Trametinib 治疗III期黑色素瘤患者长期生存数据喜人, objectType=article, longId=200218, objectId=b6bb200218dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b6bb200218dc, replyNumber=0, likeNumber=48, createdTime=2021-02-22, rootId=0, userName=pandamao2022, userId=0da336510503, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b6bb200218dc, moduleTitle=NEJM：Dabrafenib联合Trametinib 治疗III期黑色素瘤患者长期生存数据喜人, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b6bb200218dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752369, encodeId=d5901e5236911, content=<a href='/topic/show?id=2cd11e738fd' target=_blank style='color:#2F92EE;'>#Trametinib#</a>, objectTitle=NEJM：Dabrafenib加Trametinib治疗转移性黑色素瘤的五年疗效, objectType=article, longId=177709, objectId=11801e770906, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=11801e770906, replyNumber=0, likeNumber=41, createdTime=2020-05-14, rootId=0, userName=pandamao2022, userId=0da336510503, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=11801e770906, moduleTitle=NEJM：Dabrafenib加Trametinib治疗转移性黑色素瘤的五年疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=11801e770906)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752368, encodeId=830e1e52368f0, content=<a href='/topic/show?id=2cd11e738fd' target=_blank style='color:#2F92EE;'>#Trametinib#</a>, objectTitle=JCO：Dabrafenib联合Trametinib对BRAFV600突变Ⅲ期黑色素瘤患者无复发生存有益, objectType=article, longId=152422, objectId=77eb15242261, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=77eb15242261, replyNumber=0, likeNumber=35, createdTime=2018-11-11, rootId=0, userName=pandamao2022, userId=0da336510503, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=77eb15242261, moduleTitle=JCO：Dabrafenib联合Trametinib对BRAFV600突变Ⅲ期黑色素瘤患者无复发生存有益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=77eb15242261)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752366, encodeId=8f781e523663e, content=<a href='/topic/show?id=2cd11e738fd' target=_blank style='color:#2F92EE;'>#Trametinib#</a>, objectTitle=JCO：Dabrafenib和Trametinib治疗局部晚期或转移性BRAFV600突变甲状腺未分化癌, objectType=article, longId=118188, objectId=f3d911818880, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f3d911818880, replyNumber=0, likeNumber=39, createdTime=2018-09-25, rootId=0, userName=pandamao2022, userId=0da336510503, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f3d911818880, moduleTitle=JCO：Dabrafenib和Trametinib治疗局部晚期或转移性BRAFV600突变甲状腺未分化癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f3d911818880)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752367, encodeId=fd861e5236739, content=<a href='/topic/show?id=2cd11e738fd' target=_blank style='color:#2F92EE;'>#Trametinib#</a>, objectTitle=NEJM：Dabrafenib联合Trametinib可显著降低III期BRAF V600突变黑色素瘤患者的术后复发风险, objectType=article, longId=119397, objectId=b09511939ebc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b09511939ebc, replyNumber=0, likeNumber=38, createdTime=2018-08-04, rootId=0, userName=pandamao2022, userId=0da336510503, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b09511939ebc, moduleTitle=NEJM：Dabrafenib联合Trametinib可显著降低III期BRAF V600突变黑色素瘤患者的术后复发风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b09511939ebc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752365, encodeId=53f11e52365f3, content=<a href='/topic/show?id=2cd11e738fd' target=_blank style='color:#2F92EE;'>#Trametinib#</a>, objectTitle=CLIN CANCER RES：Pazopanib联合Trametinib治疗晚期软组织肉瘤, objectType=article, longId=110313, objectId=92b511031391, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=92b511031391, replyNumber=0, likeNumber=49, createdTime=2018-01-27, rootId=0, userName=pandamao2022, userId=0da336510503, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=92b511031391, moduleTitle=CLIN CANCER RES：Pazopanib联合Trametinib治疗晚期软组织肉瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=92b511031391)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752363, encodeId=32d91e52363da, content=<a href='/topic/show?id=2cd11e738fd' target=_blank style='color:#2F92EE;'>#Trametinib#</a>, objectTitle=Ann Oncol：MEK抑制剂trametinib对KRAS突变的非小细胞肺癌的II期临床研究, objectType=article, longId=47689, objectId=936f4e689f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=936f4e689f6, replyNumber=0, likeNumber=35, createdTime=2015-08-15, rootId=0, userName=pandamao2022, userId=0da336510503, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=936f4e689f6, moduleTitle=Ann Oncol：MEK抑制剂trametinib对KRAS突变的非小细胞肺癌的II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=936f4e689f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752362, encodeId=b63a1e52362d5, content=<a href='/topic/show?id=2cd11e738fd' target=_blank style='color:#2F92EE;'>#Trametinib#</a>, objectTitle=NEJM：Dabrafenib 和Trametinib联合治疗能有效提高恶性黑色素瘤患者的总生存, objectType=article, longId=44919, objectId=ce724491956, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce724491956, replyNumber=0, likeNumber=41, createdTime=2015-07-06, rootId=0, userName=pandamao2022, userId=0da336510503, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce724491956, moduleTitle=NEJM：Dabrafenib 和Trametinib联合治疗能有效提高恶性黑色素瘤患者的总生存, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ce724491956)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752364, encodeId=bb181e52364f5, content=<a href='/topic/show?id=2cd11e738fd' target=_blank style='color:#2F92EE;'>#Trametinib#</a>, objectTitle=Lancet：dabrafenib和trametinib联合治疗Val6000 BRAF突变的黑色素瘤, objectType=article, longId=51556, objectId=04735155643, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=04735155643, replyNumber=0, likeNumber=33, createdTime=2015-08-09, rootId=0, userName=pandamao2022, userId=0da336510503, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=04735155643, moduleTitle=Lancet：dabrafenib和trametinib联合治疗Val6000 BRAF突变的黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=04735155643)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752361, encodeId=ba151e5236146, content=<a href='/topic/show?id=2cd11e738fd' target=_blank style='color:#2F92EE;'>#Trametinib#</a>, objectTitle=NEJM： Dabrafenib与Trametinib联用提高黑色素瘤患者的总生存率, objectType=article, longId=42879, objectId=d0c1428e9ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d0c1428e9ec, replyNumber=0, likeNumber=36, createdTime=2015-06-25, rootId=0, userName=pandamao2022, userId=0da336510503, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d0c1428e9ec, moduleTitle=NEJM： Dabrafenib与Trametinib联用提高黑色素瘤患者的总生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d0c1428e9ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752360, encodeId=66d01e5236076, content=<a href='/topic/show?id=2cd11e738fd' target=_blank style='color:#2F92EE;'>#Trametinib#</a>, objectTitle=FDA授予GSK dabrafenib/trametinib组合疗法优先审查资格, objectType=article, longId=24620, objectId=18ab2462050, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=18ab2462050, replyNumber=0, likeNumber=45, createdTime=2013-12-16, rootId=0, userName=pandamao2022, userId=0da336510503, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=18ab2462050, moduleTitle=FDA授予GSK dabrafenib/trametinib组合疗法优先审查资格, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=18ab2462050)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752358, encodeId=8b311e5235847, content=<a href='/topic/show?id=2cd11e738fd' target=_blank style='color:#2F92EE;'>#Trametinib#</a>, objectTitle=Trametinib和Dabrafenib对BRAF突变黑色素瘤疗效优于化疗, objectType=article, longId=6885, objectId=1fc1688510, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1fc1688510, replyNumber=0, likeNumber=43, createdTime=2012-06-15, rootId=0, userName=pandamao2022, userId=0da336510503, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1fc1688510, moduleTitle=Trametinib和Dabrafenib对BRAF突变黑色素瘤疗效优于化疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1fc1688510)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752359, encodeId=33401e52359c1, content=<a href='/topic/show?id=2cd11e738fd' target=_blank style='color:#2F92EE;'>#Trametinib#</a>, objectTitle=Lancet ：MEK抑制剂Trametinib的Ⅱ期临床试验推荐剂量确定, objectType=article, longId=8271, objectId=29cd82e153, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=29cd82e153, replyNumber=0, likeNumber=45, createdTime=2012-08-04, rootId=0, userName=pandamao2022, userId=0da336510503, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=29cd82e153, moduleTitle=Lancet ：MEK抑制剂Trametinib的Ⅱ期临床试验推荐剂量确定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=29cd82e153)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Trametinib

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#神经胶质瘤# #Trametinib# #Dabrafenib#

JCO：复发/难治性儿童高级别胶质瘤的联合用药新疗法

2024-03-07发表于上海

pandamao2022 (审核中...)

前往app查看评论内容

#Trametinib#

J Clin Oncol：III期临床研究评估PD-1抑制剂Spartalizumab 联合Dabrafenib（达拉非尼）+ Trametinib（曲美替尼）治疗BRAF V600突变不可切除或转移性黑色素瘤的疗效

2022-05-06

pandamao2022 (审核中...)

前往app查看评论内容

#Trametinib#

Ann Oncol：II期临床研究ROAR更新：Dabrafenib(达拉菲尼)联合trametinib(曲美替尼)治疗BRAF V600E突变间变性甲状腺癌的疗效

2022-08-23

pandamao2022 (审核中...)

前往app查看评论内容

#Trametinib#

NEJM：Dabrafenib联合Trametinib 治疗III期黑色素瘤患者长期生存数据喜人

2021-02-22

pandamao2022 (审核中...)

前往app查看评论内容

#Trametinib#

NEJM：Dabrafenib加Trametinib治疗转移性黑色素瘤的五年疗效

2020-05-14

pandamao2022 (审核中...)

前往app查看评论内容

#Trametinib#

JCO：Dabrafenib联合Trametinib对BRAFV600突变Ⅲ期黑色素瘤患者无复发生存有益

2018-11-11

pandamao2022 (审核中...)

前往app查看评论内容

#Trametinib#

JCO：Dabrafenib和Trametinib治疗局部晚期或转移性BRAFV600突变甲状腺未分化癌

2018-09-25

pandamao2022 (审核中...)

前往app查看评论内容

#Trametinib#

NEJM：Dabrafenib联合Trametinib可显著降低III期BRAF V600突变黑色素瘤患者的术后复发风险

2018-08-04

pandamao2022 (审核中...)

前往app查看评论内容

#Trametinib#

CLIN CANCER RES：Pazopanib联合Trametinib治疗晚期软组织肉瘤

2018-01-27

pandamao2022 (审核中...)

前往app查看评论内容

#Trametinib#

Ann Oncol：MEK抑制剂trametinib对KRAS突变的非小细胞肺癌的II期临床研究

2015-08-15

pandamao2022 (审核中...)

前往app查看评论内容

#Trametinib#

NEJM：Dabrafenib 和Trametinib联合治疗能有效提高恶性黑色素瘤患者的总生存

2015-07-06

pandamao2022 (审核中...)

前往app查看评论内容

#Trametinib#

Lancet：dabrafenib和trametinib联合治疗Val6000 BRAF突变的黑色素瘤

2015-08-09

pandamao2022 (审核中...)

前往app查看评论内容

#Trametinib#

NEJM： Dabrafenib与Trametinib联用提高黑色素瘤患者的总生存率

2015-06-25

pandamao2022 (审核中...)

前往app查看评论内容

#Trametinib#

FDA授予GSK dabrafenib/trametinib组合疗法优先审查资格

2013-12-16

pandamao2022 (审核中...)

前往app查看评论内容

#Trametinib#

Trametinib和Dabrafenib对BRAF突变黑色素瘤疗效优于化疗

2012-06-15

pandamao2022 (审核中...)

前往app查看评论内容

#Trametinib#

Lancet ：MEK抑制剂Trametinib的Ⅱ期临床试验推荐剂量确定

2012-08-04

科室
- - 订阅+
  - 更多科室
工具
服务